Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 22, 2022 - Issue 6
Submit an article Journal homepage
134
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Hospital incidence and medical costs of polycythemia vera in Spain: a retrospective database analysis

Josep Darbàa Department of Economics, Universitat de Barcelona, Barcelona, SpainCorrespondence[email protected]
&
Alicia Marsàb Department of Health Economics, BCN Health Economics & Outcomes Research S.L., Barcelona, Spain
Pages 965-970 | Received 02 Jul 2021, Accepted 11 Jan 2022, Published online: 21 Feb 2022

References

  • Spivak JL. Polycythemia Vera. Curr Treat Options Oncol. 2018 Mar 7; 19(2):12.
  • Anderson LA, McMullin MF. Epidemiology of MPN: what do we know? Curr Hematol Malig Rep. 2014 Dec;9(4):340–349.
  • Iurlo A, Cattaneo D, Bucelli C, et al. New perspectives on polycythemia vera: from diagnosis to therapy. Int J Mol Sci. 2020 Aug 13 21(16):5805.
  • Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015;5:e366.
  • Griesshammer M, Kiladjian JJ, Besses C. Thromboembolic events in polycythemia vera. Ann Hematol. 2019;98(5):1071–1082.
  • Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera treatment algorithm 2018. Blood Cancer J. 2018 Jan 10;8(1):3.
  • Guglielmelli P, Vannucchi AM. Current management strategies for polycythemia vera and essential thrombocythemia. Blood Rev. 2020 Jul;42:100714.
  • Hasselbalch HC, Holmström MO. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure? Semin Immunopathol. 2019 Jan;41(1):5–19.
  • Colafigli G, Scalzulli E, Pepe S, et al. The advantages and risks of ruxolitinib for the treatment of polycythemia vera. Expert Rev Hematol. 2020 Oct;13(10):1067–1072.
  • Verstovsek S, Komrokji RS. Novel and emerging therapies for the treatment of polycythemia vera. Exp Rev Hematol. 2015;8(1):101–113.
  • Chifotides HT, Prithviraj Bose B, Verstovsek S. Givinostat: an emerging treatment for polycythemia ver. Expert Opin Investig Drugs. 2020;29(6):525–536.
  • Reiter A, Harrison C. How we identify and manage patients with inadequately controlled polycythemia vera. Curr Hematol Malig Rep. 2016 Oct;11(5):356–367.
  • Vannucchi AM, Guglielmelli P. What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia? Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):480–488.
  • Parasuraman SV, Shi N, Paranagama DC, et al. Health care costs and thromboembolic events in hydroxyurea-treated patients with polycythemia vera. J Manag Care Spec Pharm. 2018 Jan;24(1):47–55.
  • Centers for Disease Control and Prevention (CDC). International classification of diseases, Ninth Revision, Clinical Modification (ICD-9-CM). CDC; 2015. https://www.cdc.gov/nchs/icd/icd9cm.htm. Accessed 2021 May 26.
  • Centers for Disease Control and Prevention (CDC). International classification of diseases, Tenth revision, clinical modification (ICD-10-CM). CDC; 2020. https://www.cdc.gov/nchs/icd/icd10cm.htm. Accessed 2021 May 26.
  • Parliament of Spain. Law 14/2007, 3rd July, on biomedical research (BOE, 4 July 2007). Rev Derecho Genoma Hum. 2007 Jan-Jun;26. 283–325.
  • Josep Carreras Leukaemia Foundation. Polycythemia vera. Josep Carreras Leukaemia Foundation; 2020. https://www.fcarreras.org/en/polycythemia-vera_361621. Accessed 2021 Jun 28.
  • Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013 Sep;27(9):1874–1881.
  • Pereira A, Besses Raebel C, Hernandez Boluda JC, et al. Excess mortality in polycythemia vera and essential thrombocythemia. Blood. 2018 Nov;1321:3042. abstract
  • Stein BL, Moliterno AR, Tiu RV. Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options. Ann Hematol. 2014 Dec;93(12):1965–1976.
  • Karve S, Price GL, Davis KL, et al. Health care utilization and associated costs in elderly persons with non- CML myeloproliferative neoplasms: real-world evidence from a United States Medicare population. Blood. 2012;120(21):4273. abstract
  • Mehta J, Wang H, Fryzek JP, et al. Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan. Leuk Lymphoma. 2014 Oct;55(10):2368–2374.
  • Price GL, Pohl GM, Xie J, et al. A retrospective observational comparison of comorbidities between myeloproliferative neoplasm (MPN) patients and matched controls in a commercially insured US population. Blood. 2011;118(21):2060. abstract

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.